Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Oxford BioDynamics to identify NSCLC biomarkers for two global pharmas

June 9, 2017 8:19 PM UTC

Oxford BioDynamics plc (LSE:OBD) said it partnered with two "top 10" global pharmas to use its EpiSwitch epigenetic biomarker platform to identify non-small cell lung cancer (NSCLC) biomarkers from patients which may help differentiate responders from non-responders to an anti-PD-L1 therapy. The pharmas have an existing collaboration involving the therapy. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Oxford Biodynamics plc

BCIQ Target Profiles

PD-L1